UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
------------------
For the month of November 2004
Commission File Number: 001-31368
SANOFI-AVENTIS
(Translation of registrant's name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):______
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):______
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes [ ] No [X]
If "Yes" marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-________
On November 9, 2004, Sanofi-Aventis issued the press release attached
hereto as Exhibit 99.1 stating that Aventis had announced that Aventis had sent
to Genta Inc. a notice of termination of the agreements entered into by Aventis
and Genta relating to the development of Genasense(R) (oblimersen sodium).
Exhibit 99.1 is incorporated herein by reference.
On November 9, 2004, Sanofi-Aventis circulated the press announcement,
attached hereto as Exhibit 99.2, issued on behalf of the RIO (Rimonabant In
Obesity) Steering Committee announcing the results from the RIO-North America
trial that show that first year improvements in cardiovascular risk factors are
maintained in the second year of treatment. Exhibit 99.2 is incorporated herein
by reference.
EXHIBIT LIST
Exhibit No. Description
---------- -----------
Exhibit 99.1 Press Release dated November 9, 2004, issued by
Sanofi-Aventis, stating that Aventis had announced that
Aventis had sent to Genta a notice of termination of the
agreements entered into by Aventis and Genta relating to
Genasense(R)
Exhibit 99.2 Press Announcement dated November 9, 2004, issued on behalf
of the RIO Steering Committee
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Dated: November 9, 2004 SANOFI-AVENTIS
By: /s/ Jean-Claude Leroy
-----------------------------------
Name: Jean-Claude Leroy
Title: Senior Vice President &
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
---------- -----------
Exhibit 99.1 Press Release dated November 9, 2004, issued by
Sanofi-Aventis, stating that Aventis had announced that
Aventis had sent to Genta a notice of termination of the
agreements entered into by Aventis and Genta relating to
Genasense(R)
Exhibit 99.2 Press announcement dated November 9, 2004, issued on behalf
of the RIO Steering Committee